title: [Eating disorders in psychiatric patients during treatment with second generation antipsychotics].
abstract: OBJECTIVE
  To identify the frequency and characteristics of eating disorders in patients with schizophrenia treated with second generation antipsychotics.
  
  
  METHODS
  A sample included 56 patients (48 women and 8 men, mean age 28 ± 4.5 years) with schizophrenia and schizoaffective disorder. Patients received risperidone, quetiapine and olanzapine. The study employed clinical-anamnestic, endocrinological methods and assessment of eating behavior with DEBQ (The Dutch Eating Behavior Questionnaire). All of the patients had extra Body mass or obesity: extra Body mass of the 1st grade was found in 18 patients (BMI<30 kg/m²) and obesity grade 2-3 in 38 patients (BMI>30 kg/m²).
  
  
  CONCLUSIONS
  Authors identified different types of eating disorders: external, restrictive and emotiogenic as well as the relationship of their prevalence and severity with sex, drug, presence and grade of obesity. Based on these
  
  
  RESULTS
  we developed recommendations for management of patients treated with second generation antipsychotics.
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: L M
authors.initials: LM
authors.lastname: Vasilenko
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: L N
authors.initials: LN
authors.lastname: Gorobets
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: V S
authors.initials: VS
authors.lastname: Bulanov
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: A V
authors.initials: AV
authors.lastname: Litvinov
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: G P
authors.initials: GP
authors.lastname: Ivanova
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: M A
authors.initials: MA
authors.lastname: Tsarenko
authors.affiliation: Moscow State Research Institute of Psychiatry, Moscow.
authors.forename: T P
authors.initials: TP
authors.lastname: Polyakovskaya
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D001068:Feeding and Eating Disorders / Q000139:chemically induced / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000453:epidemiology; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine